We are pleased to share with you that WuXi has joined a consortium to acquire Ambrx, a San Diego based innovative biotech company.

Ambrx is a clinical-stage, top-tier innovative biologics company with a cutting-edge second-generation antibody drug conjugate (ADC) technology platform.  ADCs are expected to be one of the most important areas of monoclonal antibody development in the next decade, especially in targeted therapies for oncology, an area where Ambrx has a strong internal pipeline. Ambrx has developed a pipeline of novel product candidates that include antibody drug conjugates, or ADCs, bi- and multi-specific drug conjugates and long-acting therapeutic proteins and has strong collaborations with leading multinational pharmaceutical companies and biotechs such as Bristol-Myers Squibb, Merck, Eli Lilly, and Agensys.

This acquisition will allow WuXi to broadly access Ambrx’s best-in-class ADC platform and biologics development capabilities to better serve our global customers.  By bringing together extensive resources, geographic reach, novel technology and experienced talent, the acquisition will also not only help accelerate the advancement of innovative ADC technology and biological therapeutics, but also help Chinese patients get faster access to more advanced medicines.

 

Related links:

  1. Original press release
  2. WuXi Biologics Begins Construction of the World’s Largest Mammalian Cell Culture Manufacturing Facility Using Disposable Bioreactors
  3. IND Application for WuXi MedImmune’s Monoclonal Antibody Accepted for Review by CFDA